| |
| |
| Contributors to Volume 62 | |
| |
| |
| Preface | |
| |
| |
| Contents of Volumes 35-61 | |
| |
| |
| Authentication and Quality Assessment of the Antitussive Herb Baibu (Radix Stemonae) | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Species Specification and Authentication | |
| |
| |
| |
| Stemona Alkaloids | |
| |
| |
| |
| Quality Assessment | |
| |
| |
| |
| Conclusions | |
| |
| |
| Acknowledgement | |
| |
| |
| References | |
| |
| |
| In Vitro Propagation and Approaches for Metabolites Production in Medicinal Plants | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| In Vitro Propagation of Medicinal Plants | |
| |
| |
| |
| Production of Secondary Metabolites | |
| |
| |
| References | |
| |
| |
| Regulation of Inflammation-Mediated Chronic Diseases by Botanicals | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Transcription Factors as Mediators of Chronic Diseases | |
| |
| |
| III Role of Botanicals Against Chronic Diseases | |
| |
| |
| |
| Conclusions | |
| |
| |
| Acknowledgements | |
| |
| |
| References | |
| |
| |
| Taxol, Camptothecin and Beyond for Cancer Therapy | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Taxol | |
| |
| |
| |
| Camptothecin | |
| |
| |
| |
| New Trends in Discovery of Plant-Based Agents for Cancer Prevention and Treatment | |
| |
| |
| |
| Conclusions and Future Prospects | |
| |
| |
| References | |
| |
| |
| Effects of Beta-Glucans on Different Immune Cell Populations and Cancers | |
| |
| |
| |
| |
| Multi-Directional Immunomodulatory Anti-Cancer Effects | |
| |
| |
| |
| Effects of �-Glucans on Various Types of Immunological Populations | |
| |
| |
| |
| Structure and Form of �-Glucans in Relation to Different Effector Functions | |
| |
| |
| |
| Potential Therapeutic Anti-Cancer Effects of �-Glucans | |
| |
| |
| |
| Conclusions | |
| |
| |
| References | |
| |
| |
| Developing Phytocompounds from Medicinal Plants as Immunomodulators | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Modulation of the Immune System | |
| |
| |
| |
| Medicinal Herbs with Immunomodulatory Activities | |
| |
| |
| |
| Categorized Phytocompounds with Immunomodulatory Activities | |
| |
| |
| |
| Emerging Approaches for Modulating the Complex Systems | |
| |
| |
| |
| Challenges, Conclusion and Future Perspectives | |
| |
| |
| Acknowledgements | |
| |
| |
| References | |
| |
| |
| Chinese Herbal Medicines for Rheumatoid Arthritis | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| The History of CHMs for RA | |
| |
| |
| |
| Experimental Investigations on CHMs for RA | |
| |
| |
| |
| Clinical Study of CHMs for RA | |
| |
| |
| |
| Future Perspectives | |
| |
| |
| |
| Conclusions | |
| |
| |
| Acknowledgements | |
| |
| |
| References | |
| |
| |
| Ligusticum chuanxiong and Its Decoctions: Effects and Underlying Mechanisms of Action on Stroke | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Pharmacological Effects of TCM Decoctions on Ischaemic Stroke | |
| |
| |
| |
| Pharmacological Effects of Ligusticum chuanxiong on Ischaemic Stroke | |
| |
| |
| |
| Active Compounds Isolated from LCX | |
| |
| |
| |
| Concluding Remarks | |
| |
| |
| Acknowledgements | |
| |
| |
| References | |
| |
| |
| Potential of 'Omics' Technologies for Implementation in Research on Phytotherapeutical Toxicology | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| 'Omics'-Based Toxicology | |
| |
| |
| |
| Experimental Models | |
| |
| |
| |
| Herbal Hepatotoxicity and Toxicogenomics | |
| |
| |
| |
| Conclusions and Perspectives | |
| |
| |
| References | |
| |
| |
| Herbal Medicine: Toxicity and Recent Trends in Assessing Their Potential Toxic Effects | |
| |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Recent Concerns with Regard to the Safety of Herbal Medicines | |
| |
| |
| |
| Increasing Demand of Toxicological Evaluation of Herbal Medicines | |
| |
| |
| |
| Conclusions | |
| |
| |
| References | |
| |
| |
| Development of Drugs from Plants: Regulation and Evaluation | |
| |
| |
| |
| |
| Plants and Human Health | |
| |
| |
| |
| The History of Specific Therapy | |
| |
| |
| |
| Drug Development and the Drug Approval Process | |
| |
| |
| |
| Preclinical Studies | |
| |
| |
| |
| Clinical Studies | |
| |
| |
| |
| Post-Marketing Studies | |
| |
| |
| |
| Challenges | |
| |
| |
| |
| Conclusions | |
| |
| |
| References | |
| |
| |
| Author Index | |
| |
| |
| Subject Index | |